1. Home
  2. UTMD vs MOLN Comparison

UTMD vs MOLN Comparison

Compare UTMD & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Utah Medical Products Inc.

UTMD

Utah Medical Products Inc.

N/A

Current Price

$57.18

Market Cap

177.4M

Sector

Health Care

ML Signal

N/A

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.22

Market Cap

164.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
UTMD
MOLN
Founded
1978
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.4M
164.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
UTMD
MOLN
Price
$57.18
$4.22
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$3.75
AVG Volume (30 Days)
17.2K
4.4K
Earning Date
01-27-2026
02-11-2026
Dividend Yield
2.18%
N/A
EPS Growth
N/A
N/A
EPS
3.54
N/A
Revenue
$38,633,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$999.99
P/E Ratio
$15.83
N/A
Revenue Growth
N/A
N/A
52 Week Low
$51.26
$3.36
52 Week High
$65.56
$5.91

Technical Indicators

Market Signals
Indicator
UTMD
MOLN
Relative Strength Index (RSI) 52.88 48.42
Support Level $55.79 $4.16
Resistance Level $58.23 $4.44
Average True Range (ATR) 1.35 0.18
MACD 0.00 -0.02
Stochastic Oscillator 39.37 44.12

Price Performance

Historical Comparison
UTMD
MOLN

About UTMD Utah Medical Products Inc.

Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: